Differential Kv1.3, KCa3.1, and Kir2.1 expression in “classically” and “alternatively” activated microglia

GLIA

Volumn 65, Issue 1, 2017, Pages 106-121

  Nguyen, Hai M ^a   Grössinger, Eva M ^a   Horiuchi, Makoto ^b,c   Davis, Kyle W ^b   Jin, Lee Way ^b,c   Maezawa, Izumi ^b,c   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

KCa3.1; Kir2.1; Kv1.3; microglia; PAP 1; potassium channel; TRAM 34

Indexed keywords

ADENOSINE TRIPHOSPHATE; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MESSENGER RNA; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KV1.3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; LIPOPOLYSACCHARIDE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN ISCHEMIA; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CURRENT DENSITY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; POLARIZATION; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN SECRETION; WHOLE CELL PATCH CLAMP; ANIMAL; C57BL MOUSE; CELL CULTURE; MACROPHAGE ACTIVATION; MEMBRANE POTENTIAL; METABOLISM;

ANIMALS; CELLS, CULTURED; INTERFERON-GAMMA; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; KV1.3 POTASSIUM CHANNEL; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MEMBRANE POTENTIALS; MICE, INBRED C57BL; MICROGLIA; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 84990215091     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23078     Document Type: Article

References (69)

1. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW. 2008. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111:3991–3997.
2. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. 2007. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419–1429.
3. 2+-activated TRPM4-like currents (I CAN) in cultured mouse microglial cells. J Physiol Lond 586:427–439.
4. Beeton C, Chandy KG. Potassium channels, memory T cells and multiple sclerosis. Neuroscientist 11:550–562.
5. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942–13947.
6. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, Leehealey CJ, B SA, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414–17419.
7. Bertrand J, Venero JL. 2013. Microglia methods and protocols. New York: Springer.
8. Blomster LV, Strøbæk D, Hougaard C, Klein J, Pinborg LH, Mikkelsen JD, Christophersen P. 2016. Quantification of the functional expression of the Ca2+-activated K+ channel KCa3.1 on microglia from adult human neocortical tissue. Glia, DOI: 10.1002/glia.23040 [Epub ahead of print]
9. Cahalan MD, Chandy KG. 2009. The functional network of ion channels in T lymphocytes. Immunol Rev 231:59–87.
10. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. 2004. Potassium channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280–289.
11. Chen YJ, Nguyen HM, Maezawa I, Grössinger EM, Garing AL, Kohler R, Jin LW, Wulff H. 2015. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. J Cereb Blood Flow Metab, 0271678X15611434, first published on November 2, 2015 [Epub ahead of print].
12. Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. 2011. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 31:2363–2374.
13. Chen YJ, Singh V, Garing AL, Wulff H. 2013. The Kv1.3 blocker PAP-1 reduces infarction and neurological deficit in a rat model of reperfusion stroke. FASEB J 27:913-930.
14. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG. 2012. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59:529–546.
15. + channel gating modulators with selectivity for KCa3.1. Mol Pharmacol 86:342–357.
16. Dale E, Staal RG, Eder C, Möller T. 2016. KCa3.1-a microglial target ready for drug repurposing? Glia 64:1733–1741.
17. Decoursey TE, Chandy KG, Gupta S, Cahalan MD. 1987. Mitogen induction of ion channels in murine T lymphocytes. J Gen Physiol 89:405–420.
18. Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, Bar-Or A, Antel JP. 2012. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60:717–727.
19. Eder C, Fischer HG, Hadding U, Heinemann U. 1995. Properties of voltage-gated potassium currents of microglia differentiated with granulocyte/macrophage colony-stimulating factor. J Membr Biol 147:137–146.
20. Ferreira R, Lively S, Schlichter LC. 2014. IL-4 type 1 receptor signaling up-regulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia. Front Cell Neurosci 8:183-
21. Feske S, Wulff H, Skolnik EY. 2015. Ion channels in innate and adaptive immunity. Ann Rev Immunol 33:291–353.
22. Fordyce CB, Jagasia R, Zhu X, Schlichter LC. 2005. Microglia Kv1.3 channels contribute to their ability to kill neurons. J Neurosci 25:7139–7149.
23. Franco R, Fernandez-Suarez D. 2015. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 131:65–86.
24. Gadani SP, Cronk JC, Norris GT, Kipnis J. 2012. IL-4 in the brain: a cytokine to remember. J Immunol 189:4213–4219.
25. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330:841–845.
26. Gocke AR, Lebson LA, Grishkan IV, Hu L, Nguyen HM, Whartenby KA, Chandy KG, Calabresi PA. 2012. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol 188:5877–5886.
27. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953–964.
28. Grimaldi A, D'Alessandro G, Golia MT, Grossinger EM, Di Angelantonio S, Ragozzino D, Santoro A, Esposito V, Wulff H, Catalano M, Limatola C. 2016. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages. Cell Death Dis 7:e2174-
29. Heppner FL, Ransohoff RM, Becher B. 2015. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372.
30. + channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 27:234–244.
31. Kawabori M, Yenari MA. 2014. The role of the microglia in acute CNS injury. Metabo Brain Dis 30:381–392.
32. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. 2011. Physiology of microglia. Physiol Rev 91:461–553.
33. + channels and the microglial respiratory burst. Am J Physiol Cell Physiol 280:C796–C806.
34. Koch Hansen L, Sevelsted-Moller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. 2014. Expression of T-cell Kv1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis 8:1378–1391.
35. Koizumi S, Ohsawa K, Inoue K, Kohsaka S. 2013. Purinergic receptors in microglia: Functional modal shifts of microglia mediated by P2 and P1 receptors. Glia 61:47–54.
36. Kotecha SA, Schlichter LC. 1999. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 19:10680–10693.
37. Lam D, Schlichter LC. 2015. Expression and contributions of the Kir2.1 inward-rectifier K(+) channel to proliferation, migration and chemotaxis of microglia in unstimulated and anti-inflammatory states. Front Cell Neurosci 9:185-
38. Liu J, Xu C, Chen L, Xu P, Xiong H. 2012. Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. Cell Death Dis 3:e254-
39. Maezawa I, Jenkins DP, Jin BE, Wulff H. 2012. Microglial KCa3.1 channels as a potential therapeutic target for Alzheimer's Disease. Int J Alzheimer's Dis 2012:868972-
40. Maezawa I, Zimin P, Wulff H, Jin LW. 2011. A-beta oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 286:3693–3706.
41. Mauler F, Hinz V, Horvath E, Schuhmacher J, Hofmann HA, Wirtz S, Hahn MG, Urbahns K. 2004. Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma. Eur J Neurosci 20:1761–1768.
42. Michaelis M, Nieswandt B, Stegner D, Eilers J, Kraft R. 2015. STIM1, STIM2, and Orai1 regulate store-operated calcium entry and purinergic activation of microglia. Glia 63:652–663.
43. Möller T, Bard F, Bhattacharya A, Biber K, Campbell B, Dale E, Eder C, Gan LS, Garden GA, Hughes ZA, Pearse DD, Staal RG, Sayed FA, Wes PD, Boddeke HW. 2016. Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor. Glia 64:1788–1794.
44. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20.
45. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318.
46. + channel in rat microglia cultivated on teflon. Neurosci Lett 160:69–72.
47. + outward current in cultured rat microglia. Neurosci Lett 147:171–174.
48. Norenberg W, Gebicke-Haerter PJ, Illes P. 1994. Voltage-dependent potassium channels in activated rat microglia. J Physiol Lond 475:15–32.
49. Peng Y, Lu K, Li Z, Zhao Y, Wang Y, Hu B, Xu P, Shi X, Zhou B, Pennington M, Chandy KG, Tang Y. 2014. Blockade of Kv1.3 channels ameliorates radiation-induced brain injury. Neuro-Oncology 16:528–539.
50. Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari AA. 2007. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) 232:1338–1354.
51. Perry VH, Nicoll JA, Holmes C. 2010. Microglia in neurodegenerative disease. Nat Rev Neurol 6:193–201.
52. Prinz M, Priller J. 2014. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312.
53. Prinz M, Priller J, Sisodia SS, Ransohoff RM. 2011. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14:1227–1235.
54. Rangaraju S, Gearing M, Jin LW, Levey A. 2015. Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease. J Alzheimer's Dis 44:797–808.
55. Ransohoff RM, Cardona AE. 2010. The myeloid cells of the central nervous system parenchyma. Nature 468:253–262.
56. Reich EP, Cui L, Yang L, Pugliese-Sivo C, Golovko A, Petro M, Vassileva G, Chu I, Nomeir AA, Zhang LK, Liang X, Kozlowski JA, Narula SK, Zavodny PJ, Chou CC. 2005. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol 35:1027–1036.
57. + channels in microglia deactivated by TGF-beta. Am J Physiol Cell Physiol 279:C1123–1134.
58. + channels for lysophosphatidic acid-induced microglia migration. Eur J Neurosci 19:1469–1474.
59. + and Cl- channels and their involvement in proliferation of rat microglial cells. Glia 17:225–236.
60. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. 2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254–1270.
61. Siddiqui T, Lively S, Ferreira R, Wong R, Schlichter LC. 2014. Expression and contributions of TRPM7 and KCa2.3/SK3 channels to the increased migration and invasion of microglia in anti-inflammatory activation states. PLoS ONE 9:e106087.
62. Tarcha EJ, Chi V, Munoz-Elias EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP. 2012. Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther 342:642–653.
63. + channel in macrophages. J Biol Chem 281:37675–37685.
64. + current reveals microglial activation induced by HIV-1 Tat protein. Glia 33:181–190.
65. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD. 2013. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 10:35-
66. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. 2003. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest 111:1703–1713.
67. + channel expression during B-cell differentiation: Implications for immunomodulation and autoimmunity. J Immunol 173:776–786.
68. + channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 97:8151–8156.
69. Xie L, Sun F, Wang J, Mao X, Xie L, Yang SH, Su DM, Simpkins JW, Greenberg DA, Jin K. 2014. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. J Immunol 192:6009–6019.